Continuous Outcome Non-Inferiority Trial
A Continuous Outcome Non-Inferiority Trial is a clinical trial method that aims to show that a new treatment is non-inferior to an existing treatment in terms of a continuous outcome, where an acceptable difference is defined. Continuous outcomes include numerical values such as cholesterol levels, pain intensity or weight loss, which can be measured on a scale.
Novustat is your experienced partner and advises you on all aspects of statistics, from data analysis to the interpretation of results, and helps you to gain maximum insight from your data sets. Contact us without obligation for further information!
Use our online calculator to quickly and easily calculate the optimal sample size for your non-inferiority study with continuous outcomes.
Goal and concept
The goal of a non-inferiority trial is to demonstrate that the new treatment may not be better, but is within a predetermined acceptable margin of difference from the existing treatment. This type of study is particularly useful when the new treatment offers advantages — such as lower costs, fewer side effects, or easier administration —that could offset any potential loss of efficacy.
Calculating the sample size
Calculating the sample size is crucial to ensuring that the study has sufficient statistical power. This helps ensure valid and reliable results. The calculation takes into account the acceptable difference, the standard deviation of the results, the significance level, and the power. Our online calculator helps you accurately determine the required sample size.
Application and requirements
An example of a continuous outcome non-inferiority trial would be the comparison of two cholesterol-lowering drugs. Suppose the new drug lowers LDL cholesterol by an average of 20 mg/dL and the existing drug by 22 mg/dL. The study shows that the new drug is not worse if a difference of up to 5 mg/dL is considered clinically irrelevant. Such a study requires clear definitions of the non-inferiority threshold and robust statistical analyses in order to obtain valid results.
Guidelines for calculating sample size for non-inferiority studies with continuous outcomes
The calculation of the sample size is based on the expected difference between the groups, the standard deviation of the results, the significance level, and the statistical power. These factors ensure that the sample is large enough to yield valid and meaningful results. It ensures that the sample is large enough to yield valid and reliable results. These parameters ensure that the study is robust enough to demonstrate non-inferiority.
Significance level (alpha)
The significance level (α) defines the risk of an error of the first kind, i.e. the probability of finding a difference even though none exists. An alpha of 0.05 is usually selected, which corresponds to a 5% risk .
Power (1-Beta)
The power (1-β) indicates how likely it is that a true non-inferiority is correctly detected. A power of 80% to 90% ensures that the study is sensitive enough to detect a clinically relevant difference.
Standard deviation (σ)
The standard deviation (σσ) indicates the variability of the measured results within the groups. Greater variability requires a larger sample size to yield accurate results.
Non-inferiority limit (Δ)
The non-inferiority threshold (ΔΔ) defines the maximum acceptable difference between the groups at which the new treatment is still considered non-inferior. For example, a difference of 5 mg/dL in cholesterol levels could be considered acceptable.
Formula for calculation
The sample size is calculated using the following formula:
Here, f(α, β) represents the Z-scores, which are determined by the significance level and the power. σ represents the standard deviation of the results, and Δ represents the non-inferiority margin. This formula ensures that the sample size is large enough to provide valid and statistically sound results in your non-inferiority study.
Frequently asked questions
What is a continuous outcome non-inferiority trial?
This study design tests whether a new treatment is not clinically meaningfully worse than the comparator for a continuous outcome.
When is a non-inferiority trial appropriate?
It is appropriate when the new treatment offers other advantages, such as fewer side effects, lower costs, or easier administration.
What does the non-inferiority margin represent?
It defines the largest still acceptable disadvantage of the new treatment versus the control.
Which parameters determine the sample size?
The expected difference, standard deviation, non-inferiority margin, significance level, and power influence the required sample size.
How is a continuous outcome evaluated?
The groups are compared using numerical measurements; the uncertainty of the estimated difference is assessed relative to the predefined margin.
Plan non-inferiority trials with continuous outcomes robustly.
NOVUSTAT supports you in justifying the non-inferiority margin, modeling expected variability, planning sample size, and conducting the statistical analysis.
